Physician profile
Michele Nobs
NPI 1386619138
$15,097.03
in general payments reported to CMS, 2019-2025
70 companies · $3,889 in 2025
The $3,889 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $327 · 2022: $2,721 · 2023: $4,316 · 2024: $3,843 · 2025: $3,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,101.04 |
| Education | $947.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $1,535.05 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Janssen Biotech, INC. | $976.47 | 2021-2025 | Darzalex, Talvey, Erleada |
| Novartis Pharmaceuticals Corporation | $972.95 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $930.83 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $740.30 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $591.37 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $568.17 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $532.90 | 2021-2025 | Opdivo, Opdualag |
| Emd Serono, INC. | $508.20 | 2023-2025 | Bavencio |
| Eisai INC. | $465.61 | 2022-2024 | |
| Celgene Corporation | $448.67 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Abbvie INC. | $439.36 | 2021-2025 | |
| Genzyme Corporation | $414.60 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $398.36 | 2022-2025 | |
| Incyte Corporation | $384.85 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $341.94 | 2021-2025 | Jemperli, Ojjaara, Zejula |
| Genentech USA, INC. | $314.28 | 2023-2025 | Kadcyla, Phesgo, Perjeta |
| Takeda Pharmaceuticals U.S.A., INC. | $264.41 | 2022-2025 | Fruzaqla, Iclusig, Alunbrig |
| Lilly USA, LLC | $261.58 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $243.35 | 2022-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $201.11 | 2022-2025 | Libtayo |
| Gilead Sciences, INC. | $197.41 | 2021-2025 | Trodelvy |
| Amgen INC. | $180.51 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.72 | 2022-2025 | Gilotrif |
| Karyopharm Therapeutics INC. | $175.53 | 2021-2025 | Xpovio |
| Beigene USA, INC. | $157.45 | 2022-2025 | Tevimbra, Brukinsa |
| Jazz Pharmaceuticals INC. | $151.42 | 2022-2025 | |
| Tempus Ai, INC | $145.17 | 2024 | |
| Astellas Pharma US INC | $143.85 | 2022-2024 | Xtandi, Padcev |
| Taiho Oncology, INC. | $143.34 | 2022-2025 | |
| Beone Medicines USA, INC. | $143.11 | 2025 | Brukinsa, Tevimbra |
| Sobi, INC | $135.15 | 2023-2025 | |
| Stemline Therapeutics INC. | $115.56 | 2022-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $106.28 | 2022-2025 | |
| Array Biopharma INC | $93.02 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Springworks Therapeutics, INC. | $89.90 | 2024-2025 | Ogsiveo |
| Adc Therapeutics America, INC. | $77.89 | 2023-2025 | |
| Blueprint Medicines Corporation | $77.69 | 2022-2023 | Ayvakit |
| Dendreon Pharmaceuticals LLC | $76.44 | 2024-2025 | Provenge |
| Servier Pharmaceuticals LLC | $75.80 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $74.42 | 2021-2024 | Myrisk |
| Tersera Therapeutics LLC | $72.08 | 2022-2025 | Zoladex |
| Mirati Therapeutics, INC. | $66.38 | 2023-2024 | Krazati |
| Sumitomo Pharma America, INC. | $65.53 | 2023-2024 | Orgovyx |
| Puma Biotechnology, INC. | $60.52 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $55.22 | 2023 | Imbruvica, Epkinly |
| Legend Biotech USA INC. | $53.46 | 2025 | Carvykti |
| Morphosys, US INC. | $50.79 | 2022-2023 | Monjuvi |
| Rigel Pharmaceuticals, INC. | $50.20 | 2022-2023 | Rezlidhia, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $49.90 | 2024-2025 | Onivyde |
| Geron Corporation | $46.12 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $42.39 | 2024-2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $35.11 | 2024 | Rolvedon |
| Azurity Pharmaceuticals, INC. | $33.18 | 2024-2025 | Danziten, Vivimusta |
| Alexion Pharmaceuticals, INC. | $30.07 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $29.15 | 2023-2024 | Xarelto |
| Adaptive Biotechnologies Corporation | $27.16 | 2022 | |
| Recordati_rare_diseases_inc. | $26.96 | 2025 | Enjaymo |
| Kite Pharma, INC. | $24.00 | 2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $23.18 | 2024 | Cosela |
| Sun Pharmaceutical Industries INC. | $21.79 | 2025 | |
| Immunocore Limited | $21.58 | 2025 | Kimmtrak |
| Pharmaessentia USA Corporation | $21.49 | 2025 | Besremi |
| G1 Therapeutics, INC. | $20.82 | 2023 | Cosela |
| Corcept Therapeutics | $20.23 | 2025 | Korlym |
| Telix Pharmaceuticals | $19.19 | 2024 | Illuccix |
| Mylan Institutional INC. | $18.05 | 2022 | |
| Genmab U.S., INC. | $15.22 | 2022 | |
| Cti Biopharma Corp. | $14.95 | 2023 | Vonjo |
| Secura Bio, INC. | $8.29 | 2022 |
Drugs and devices associated with these payments
Keytruda $766Enhertu $661Tukysa $415Lenvima $389Kisqali $325Darzalex $285Venclexta $279Reblozyl $255Nubeqa $246Welireg $229Opdivo $227Talvey $225Cabometyx $207Erleada $201Lynparza $187Jaypirca $183Sarclisa $177Carvykti $176Imfinzi $176Tecvayli $175Libtayo $167Bavencio $159Ibrance $154Jakafi $150Verzenio $149Monjuvi $148Jemperli $147Pluvicto $139Scemblix $138Padcev $129Imbruvica $126Fruzaqla $125Brukinsa $125Adcetris $125Zepzelca $121Lutathera $116Tevimbra $115Lonsurf $109Inqovi $109Xofigo $108Orgovyx $107Doptelet $105Elrexfio $105Orserdu $100Xtandi $99.50Pemazyre $97.74Rybrevant $95.29Fotivda $93.76Xpovio $90.79Trodelvy $89.09Bosulif $89.05Epkinly $88.57Datroway $85.74Akeega $81.57Balversa $81.57Gilotrif $81.53Iclusig $80.77Provenge $76.44Opdualag $76.40Phesgo $74.81Kadcyla $74.81Perjeta $74.81Mektovi $73.90Braftovi $73.90Stivarga $67.03Ogsiveo $66.90Polivy $66.47Krazati $66.38Ojjaara $64.46Jevtana $62.56Lorbrena $60.44Benefix $59.33Xyntha $59.33Hympavzi $59.33Herceptin $58.98Fabhalta $58.43Lupron Depot $56.59Tibsovo $56.42Zoladex $56.08Tecentriq Hybreza $55.70Talzenna $54.26Vitrakvi $52.05Tecentriq $51.72Calquence $51.36Enjaymo $49.93Onivyde $49.90Alecensa $49.72Xalkori $48.37Emrelis $47.46Zynlonta $47.28Rytelo $46.12Injectafer $45.33Vonjo $44.83Tagrisso $44.46Cosela $44.00Cablivi $43.90Inlyta $42.37Alunbrig $41.81Piqray $41.66Columvi $41.48
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Nobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.